---
schema_version: "secwatch.filing_event.v1"
accession: "0001357459-26-000017"
form_type: "8-K"
ticker: "PALI"
cik: "0001357459"
company_name: "PALISADE BIO, INC."
filed_at: "2026-08-10T20:18:21+00:00"
generated_at: "2026-08-10T20:19:11.344811+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Palisade Bio reports Q2 2026 net loss $10.6M; advances PALI-2108 into Phase 2

## Summary
- Q2 2026 net loss $10.6M ($0.05/share) vs $2.8M ($0.58) year ago; R&D spend $7.4M vs $1.7M.
- Cash $125.2M at June 30, 2026; funded through Phase 2 readouts (UC 2H 2027, CD early 2028).
- Phase 1 PALI-2108: 5/5 UC clinical response, 2/5 remission; FSCD SES-CD reduced ~47.5% (3.8 points).
- Phase 2 ASCENTRA-UC enrollment expected 2H 2026; ASCENTRA-CD IND expected 2H 2026, trial start 1Q 2027.
- Board adds Robert Baltera and Jordan Zwick; $0.5M license revenue milestone from Newsoara.

## SEC filing metadata
- accession: 0001357459-26-000017
- form_type: 8-K
- ticker: PALI
- cik: 0001357459
- company_name: PALISADE BIO, INC.
- filed_at: 2026-08-10T20:18:21+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357459/000135745926000017/0001357459-26-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357459/000135745926000017/pali-20260810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001357459-26-000017
- JSON: https://secwatch.observer/filing/0001357459-26-000017.json
- Plain text: https://secwatch.observer/filing/0001357459-26-000017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.